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Purpose: The purposes of this study were to evaluate the long-term results of different autogenous conduits used for
infrainguinal bypass when ipsilateral greater saphenous vein (IGSV) is absent or inadequate and to determine the impact
on the contralateral lower extremity.
Methods: The study was performed as a retrospective evaluation of a prospective vascular registry together with review of
patient records and telephone follow-up.
Results: From January 1990 to June 2000, 226 autogenous infrainguinal reconstructions were performed in 203 patients
without adequate IGSV. The patients consisted of 128 men and 98 women, with a mean age of 69 years. Prevalent risk
factors included diabetes (51%) and prior coronary bypass (46%). Limb salvage was the predominant indication (93%),
and 59% of the procedures were secondary reconstructions. All bypasses were completed with autogenous vein, which
included contralateral greater saphenous vein (CGSV; 31%), single-segment lesser saphenous vein (5%), single-segment
arm vein (19%), and autogenous composite vein (45%). Bypasses were performed to the tibial and pedal arteries in 84%
of the cases. The 30-day mortality and graft occlusion rates were 1% and 9%, respectively. The overall postoperative
morbidity rate was 24%, with a 7% rate of major complications. Follow-up was complete in 95% of patients over a mean
period of 24 months (range, 0.1 to 106 months). The 5-year primary patency rates were significantly better for CGSV
compared with autogenous composite vein grafts (61%  7% versus 39%  6%; P < .009). The 5-year secondary patency
(60% to 73%) and limb salvage (78% to 81%) rates did not differ significantly between the three groups. Follow-up of the
contralateral lower limb revealed that nine of 226 limbs (4%) were amputated at a mean of 36 months after the ipsilateral
bypass. The overall 5-year contralateral limb preservation rate was 90% 3%. Contralateral vein harvest and the presence
of diabetes did not affect the need for bypass or amputation of the contralateral limb.
Conclusion: For most patients with inadequate IGSV, the CGSV is the alternative conduit of choice because of its length,
superior performance, ease of harvest, and minimal risk to the donor limb. (J Vasc Surg 2002;35:1085-92.)
Single-segment greater saphenous vein (GSV) has
proven to be the conduit of choice for infrainguinal arterial
reconstruction because of its length, size compatibility, and
durability. Equivalent good results have been reported with
the GSV used in the in situ, reversed or nonreversed,
transposed configurations.1-3 Ipsilateral GSV (IGSV),
however, is inadequate or absent in as many as 40% of
patients needing lower extremity revascularization.4 Dur-
ing the last 10 years, our institutional experience found the
IGSV to be absent or inadequate in about 20% of cases. The
optimal alternative conduit for lower extremity revascular-
ization in such circumstances remains an issue of active
debate. Prosthetic grafts have been shown to be inferior to
autogenous conduits for infragenicular reconstructions.5
Of the available autogenous conduits, however, some au-
thors have advocated the use of arm veins in preference over
the contralateral GSV (CGSV), especially in patients with
diabetes.6 The rationale for this approach is the avoidance
of the risk of lower limb wound complications and the
preservation of the CGSV either for subsequent infraingui-
nal bypass in the contralateral limb or for coronary revas-
cularization, all of which are more likely in the diabetic
population. In contradistinction to this, our policy for the
prioritization of vein usage has been to use the best vein
available for the immediate problem at hand. Therefore,
the CGSV is our preferred conduit of choice when the
IGSV is unavailable, unless the contralateral limb also has
evidence of advanced ischemia (disabling claudication, rest
pain, or tissue loss). In this retrospective study, we sought
to evaluate the long-term results of our strategy for infrain-
guinal arterial reconstruction in the absence of IGSV. In
particular, the impact on the outcome of the contralateral
donor leg is examined.
METHODS
A retrospective evaluation was performed on all auto-
genous infrainguinal bypass procedures done in the absence
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of IGSV at the Brigham and Women’s Hospital from
January 1990 to June 2000. Data were retrieved from a
computerized registry in which demographics, risk factors,
procedure variables, and follow-up information have been
prospectively entered for all vascular surgery patients at our
institution since 1975. A detailed review of computerized
inpatient records, office charts, operative reports, and vas-
cular laboratory and angiographic reports was performed.
In addition, telephone follow-up of patients with incom-
plete information from the previous sources was per-
formed.
The techniques of vein harvest, preparation, and cre-
ation of composite vein grafts have been previously de-
scribed.7 As mentioned, the CGSV was the preferred
choice of conduit when the IGSV was unavailable and when
the contralateral limb did not have disabling claudication,
rest pain, or tissue loss. Harvest of this vein usually was
started in the groin, proceeding distally until an adequate
length of vein was obtained. Since the early 1990s, increas-
ing reliance has been placed on preoperative duplex scan
vein mapping to guide the order in which ectopic veins
were explored. Obvious thrombosis, wall thickening, and
noncompressibility were indications of an unusable vein. If
a minimum diameter of 2 to 3 mm was seen in an otherwise
normal vein on duplex scan, it was explored. Our intraop-
erative criteria for an optimal vein were a minimum diam-
eter of 3.5 to 4 mm, easy distensibility with gentle inflation,
and absence of sclerotic areas. Vein segments that did not
meet these criteria were excised or repaired. Intraoperative
angioscopy was not used in any of these cases.
Emphasis was placed on minimizing ischemic time to
the vein graft and optimizing the size match between the
graft and the native vessel at the anastomoses. Valve lysis,
when necessitated, was performed with the retrograde
modified Mills valvulotome with the vein under distension.
Completion arteriography was routinely performed in all
cases, and recently, we have also used intraoperative duplex
scan imaging to identify occult problems in the conduit.
The venous conduits that were used included CGSV,
single-segment lesser saphenous vein, single-segment arm
vein (SSAV), and autogenous composite vein (ACV). The
latter were comprised of GSV remnants, long saphenous
vein, basilic vein, and cephalic vein from all available ex-
tremities. The basilic vein was almost always used in a
nonreversed orientation because of its usual tapered anat-
omy. Because the length of conduit was often the limiting
factor in these cases, we strived to use the most acceptable
distal inflow and proximal outflow sites possible. The use of
postoperative anticoagulation therapy, apart from aspirin,
was not routine but dependent on the surgeon’s judgement
of the graft being at high risk for early failure. Only 27% of
patients in this series underwent postoperative anticoagu-
lation therapy.
Follow-up examinations occurred within the first
month of surgery, then at 3 monthly intervals for the first
year and semiannually thereafter. Duplex graft scan and
noninvasive hemodynamic studies (ankle-brachial index
[ABI]) were used for detection of occult graft lesions. A
return of symptoms, change in physical examination, focal
increase in graft velocity (300 cm/s or ratio 3:1), or
decreased overall graft velocity (45 cm/s) in a normal
caliber graft were considered evidence of significant lesions
and usually lead to arteriography and revision as indicated.8
Minor amputations were defined as those resulting in a foot
that could still be used for ambulation. Limb salvage was
correspondingly defined as freedom from transtibial or
above-knee amputation. Primary, assisted-primary, and sec-
ondary patency rates were defined in accordance with the
suggested reporting standards of the Society for Vascular
Surgery/International Society for Cardiovascular Surgery
Ad Hoc Committee.9 Survival, graft patency, and limb
salvage rates were calculated with the life table method.
Standard errors were calculated with the Greenwood
method, and comparisons between groups were made with
the Mantel-Cox log-rank analysis. Categoric variables were
compared with 2 analysis, and differences between per-
centages were evaluated with the t test. A P value of less
than .05 was considered to represent statistical significance.
Lost to follow-up was defined as the last patient visit or
contact being greater than 18 months.
RESULTS
From January 1, 1990, to June 30, 2000, 226 autoge-
nous infrainguinal reconstructions were performed in 203
patients without adequate IGSV, out of a total of 1126
bypasses constructed in 910 patients at the Brigham and
Women’s Hospital. The 128 male and 98 female patients
had a mean age of 69 years (range, 37 to 92 years).
Significant risk factors included diabetes mellitus (DM;
51%), smoking (27%), hypertension (65%), and coronary
artery disease (70%), with 46% of cases having undergone
prior coronary bypass (CABG). Limb salvage was the pre-
dominant indication for surgery in 93% of patients (rest
pain 39%, ulcer 34%, and gangrene 20%). Most of the
bypasses were secondary reconstructions (59%), performed
after a previous failed lower limb bypass. Reasons for the
unavailability of the IGSV included prior leg bypass (47%),
prior CABG (24%), both leg bypass and CABG (22%), vein
sclerosis/varicosity (4%), prior varicose vein stripping (2%),
and history of deep vein thrombosis (0.9%).
The proximal anastomosis originated at the common
femoral artery in 54% of the cases, the proximal superficial
femoral artery in 15%, the distal superficial femoral artery in
11%, the profunda femoris artery in 6%, and the popliteal
artery in 14%. The distal anastomosis was at the tibial-pedal
level in 84% and at the popliteal level in 16%. Of the venous
conduits used, single-segment CGSV comprised 31% (re-
versed 6%, nonreversed 25%), SSAV 19%, single-segment
lesser saphenous vein 5%, and ACV 45% (Table I). Five
patients had a suitable CGSV left intact as the result of
clinical evidence of significant ischemia in the contralateral
limb.
The overall postoperative morbidity rate was 24%, but
major morbidity occurred in only 7% (myocardial infarction
2%, stroke 1%, renal failure 1%, pulmonary failure 3%).
Donor site wound complications occurred in 6% and in-
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cluded infection (4%), hematoma (1%), and dehiscence
(1%). The early graft occlusion rate was 9%, resulting in a
30-day major amputation rate of 3% for the index limb.
Three patients underwent planned staged contralateral
limb bypass for concurrent critical ischemia within 30 days.
No contralateral limb amputations were performed within
30 days of the ipsilateral bypass. The 30-day mortality rate
was 1%. Patients were followed for a mean of 24 months
and a median of 15 months (range, 0.1 to 106 months).
The lost to follow-up rate was 5%.
The overall 5-year patency and limb salvage rates for
CGSV, SSAV, and ACV groups are shown in Table II. The
overall 5-year survival rate was 45%  5%. Primary patency
rates for CGSV grafts were significantly better compared
with ACV grafts (61% 7% versus 39% 6%; P .009; Fig
1; Appendix A, online only). No significant difference in
assisted-primary patency, secondary patency, or limb sal-
vage rates was seen between the three types of conduits. As
expected, primary bypasses showed superior patency and
limb salvage rates compared with secondary reconstruc-
tions (5-year secondary patency rate, 82% 5% versus 63%
 5%; P  .006). On follow-up, CGSV grafts also needed
fewer graft revisions compared with ACV grafts (15% versus
26%, respectively; P  .04).
In the entire cohort of 203 patients who underwent
index limb bypasses in the absence of IGSV, nine contralat-
eral limbs (4%) were amputated at a mean of 36 months and
a median of 30 months (range, 1.8 to 82 months) after the
ipsilateral bypass. Reasons for the limb loss and time inter-
val to the limb loss are shown in Table III. Twenty-six
contralateral limb bypasses (12%) were performed at a
mean of 16 months and a median of 10 months (range, 0.2
to 82 months) after the ipsilateral bypass. Overall interven-
tion (either bypass or amputation) in the contralateral limb
was 16%. Overall 5-year freedom from bypass and amputa-
tion of the contralateral limb rates were 81% 4% and 90%
 3%, respectively (Fig 2; Appendices B and C, online
only). Interestingly, the presence of DM did not influence
the need for contralateral bypass or limb loss (5-year con-
tralateral limb preservation rate in DM versus no DM, 88%
 6% versus 90%  5%; P  .44; Fig 3; Appendices D and
E, online only).
Analysis of the subgroup of 111 contralateral limbs in
which any segment of leg vein had been harvested as all or
part of the index graft (71 of 111 were donor limbs for
single-segment CGSV grafts) revealed that the 5-year cu-
mulative freedom from bypass and amputation rates were
84% 5% and 87% 7%, respectively. In comparison with
the group of 115 limbs in which no contralateral leg vein
was used for conduit, the corresponding rates were 79% 
6% and 94%  3%; no significant difference was seen in
contralateral limb bypass or amputation rates between the
two groups (Fig 2).
Contralateral limb ABIs were available in only 43% of
patients at the time of the ipsilateral bypass. For the group
of patients who had CGSV harvest, the mean and median
ABI was 0.8 (range, 0.4 to 1.6). For the group of patients
who eventually needed contralateral limb amputation, the
initial mean ABI was 0.7, with a median of 0.6 (range, 0.4
to 1.2).
DISCUSSION
Of the many variables that affect the success of infrain-
guinal arterial bypass surgery, the quality of the conduit
probably exerts the greatest influence. Single-segment GSV
is the conduit of choice because of its length, ease of
harvest, size compatibility with the arteries of the extremity,
and its proven long-term durability. However, with the
increasing incidence rate of coronary artery bypass grafting
and the high proportion of reoperative lower extremity
arterial reconstructions in the vascular population,10 the
IGSV is often unavailable to the surgeon. In our experi-
ence, the IGSV was absent or inadequate in about 20% of
cases. The choice of alternative conduit is influenced by
many factors, including the clinical status of the contralat-
eral limb, anticipated dialysis access needs for patients with
end-stage renal disease, and whether CABG is imminently
indicated. Further considerations pertain to the long-term
performance of SSAV and GSV grafts and whether the
effort expended in ACV grafting translates into improved
graft patency and limb salvage rates compared with the use
of prosthetic grafts with or without adjuncts.
Our institutional preference is to complete all infrain-
guinal arterial reconstructions with autogenous tissue, used
as single-segment conduits whenever possible. When the
Table I. Characteristics of conduit usage in patients
without IGSV
Characteristics
Mean age (y) 69
Diabetes 51%
Prior CABG 46%
Reoperative bypass 59%
Conduit types
CGSV 71 (31%)
SSLSV 10 (5%)
SSAV 43 (19%)
Composite arm vein 38 (17%)
Composite leg vein (one leg) 12 (5%)
Composite leg vein (two legs) 25 (11%)
Composite arm-leg vein 27 (12%)
Total 226 (100%)
SSLSV, Single-segment lesser saphenous vein; SSAV, single-segment arm
vein.
Table II. Overall 5-year patency and limb salvage rates
Rates
CGSV
(n  71)
SSAV
(n  43)
ACV
(n  102)
Primary patency 61%  7%* 50%  9% 39%  6%*
Primary-assisted 65%  7% 62%  11% 58%  7%
Secondary patency 73%  7% 60%  12% 63%  7%
Limb salvage 81%  7% 81%  8% 78%  5%
*P  .009.
Overall 5-year survival rate, 45%  5%; ACV, Autogenous composite vein.
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 6 Chew et al 1087
IGSV is unavailable or inadequate, the CGSV is our pre-
ferred conduit of choice, provided no disabling claudica-
tion, ischemic rest pain, or tissue loss exist in that limb.
Duplex vein mapping has facilitated the triage of conduit
usage and is performed whenever ectopic vein sources are
necessitated or when the quality of the GSV is in question.
The 30-day graft occlusion rate of 9% in this series is
reflective of both the high percentage of secondary recon-
structions and the substantial fraction of multisegment
(ACV) grafts and is similar to other series of complex
infrainguinal reconstructions.11
The superior performance of CGSV grafts over ACV
grafts is evidenced by the statistically significant difference
in 5-year primary patency rates. Despite the lack of statisti-
cal difference in patency between CGSV and SSAV grafts,
arm vein grafts clearly are less frequently usable as single-
segment conduits because of their shorter length and the
frequent need to excise sclerotic segments. In this study,
SSAV grafts comprised only 19% of the cases, and ACV
grafts in which arm veins were used formed 29% of all the
conduits. Although our experience with ACV grafts
showed durable 5-year assisted-primary and secondary pa-
tency rates (63% and 65%, respectively), an intensive graft
surveillance protocol and a high graft revision rate (27%)
were necessary to achieve those results.12 In this study,
CGSV grafts needed significantly fewer graft revisions com-
Fig 1. Overall primary patency rates of CGSV, SSAV, and ACV grafts.
Table III. Characteristics of patients with contralateral limb loss
Patient Any CLV Interval* Indication Comment
GB Yes 2 months Rest pain, ESRF, debility Primary amputation
UA Yes 6 months Heel ulcer, debility Primary amputation
RG No 2.5 years Gangrene Failed prior bypass
RW Yes 2.5 years Rest pain Failed prior bypass
CH No 4 years Necrotizing infection Primary amputation
LP No 4 years Rest pain Failed thrombectomy
AP Yes 4.5 years Poor healing TMA Failed bypass
PR Yes 5 years Rest pain, ESRF, debility Primary amputation, contracture
PL No 7 years Rest pain Failed bypass
*Time interval between ipsilateral limb bypass and contralateral limb amputation. CLV, Any vein harvested from contralateral limb; ESRF, end-stage renal
failure; TMA, transmetatarsal amputation.
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pared with ACV grafts, and the difference in revision rate
between CGSV and SSAV grafts just fell short of statistical
significance. Therefore, ACV grafting is not only a more
time consuming and technically demanding operation
compared with harvesting the CGSV but also mandates
aggressive follow-up and graft revision to maintain contin-
ued patency. The lack of difference in secondary patency
and limb salvage rates between the three types of conduits
attests to the efficacy of aggressive graft surveillance.
The performance of SSAV grafting has approached that
of GSV grafting, as shown in this study and other re-
ports,13,14 but not all surgeons have had similar success.15
Generally, the harvest of arm veins is more laborious be-
cause of their numerous tributaries and close proximity to
cutaneous nerves. Furthermore, their thinner wall necessi-
tates careful handling to avoid trauma and twisting of the
graft. In contrast, most vascular surgeons are facile with the
harvest and handling of the GSV.
Does the harvest of the CGSV compromise subsequent
coronary revascularization? Studies have shown that the
incidence rate of subsequent CABG after leg bypass is very
low, about 2% at 5 years and 3% at 10 years.16 In this study,
Fig 2. A, Rates of freedom from contralateral limb bypass. B,
Contralateral limb preservation rates.
Fig 3. A, Rates of freedom from contralateral limb bypass: pa-
tients with diabetes versus patients without diabetes. B, Contralat-
eral limb preservation rates: patients with diabetes versus patients
without diabetes.
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only 3% of patients needed CABG after the lower limb
bypass surgery. A major reason for this is that a large
percentage of patients already had their coronary bypass
surgery before the leg bypass procedure. Even so, an in-
creasing array of alternative choices is available for coronary
revascularization in the vein-limited patient (eg, percutane-
ous angioplasty/stenting, radial artery, gastroepiploic ar-
tery, and bilateral internal mammary arterial grafting). In
our opinion, the argument to save the CGSV for a low
likelihood coronary vein graft in the future has been over-
stated.
Does the harvest of the CGSV compromise the out-
come of the contralateral lower limb? In the overall study
population, of which about half had diabetes, only 4% lost
their contralateral leg at a mean interval of 3 years after the
ipsilateral bypass. The 5-year contralateral limb preserva-
tion rate was 90%. No difference was seen in the require-
ment for bypass or amputation in the contralateral limb
between patients who had contralateral leg vein harvest
versus patients who did not. Furthermore, contrary to
results from other series,6,17 the presence of DM had no
influence on the need for contralateral limb bypass or
amputation. Most of the few patients who lost their con-
tralateral limbs had progression of their vascular disease and
lack of available autogenous conduits. No patients lost their
contralateral limbs as a direct result of the vein harvest.
Other authors have argued against the use of contralat-
eral leg vein in patients with diabetes, citing a higher rate of
subsequent contralateral leg bypass. One recent study ex-
amined the fate of the contralateral leg in patients who
underwent infrainguinal bypass.17 Overall, only 20% of the
contralateral limbs in that study needed subsequent inter-
vention; however, the relative risk was significantly higher
for patients with diabetes, coronary disease, and younger
age. Our study differs from theirs in specifically examining
the long-term outcomes of patients initially seen with in-
adequate IGSV, which is the clinical problem facing the
surgeon. Despite a similar population in terms of age,
prevalence of diabetes, and overall survival rate, our results
show no adverse long-term consequence to CGSV harvest
in patients with diabetes. We continue to believe that the
minority of patients needing contralateral revascularization
in the future can be adequately served with alternative arm
vein conduits at that point in time, if neither GSV is available.
The results of this study support the superiority and
safety of use of the CGSV for lower extremity bypass in
patients who do not manifest advanced contralateral isch-
emia. Our study suffers from a lack of rigorously applied,
objective criteria to define conduit preferences in a prospec-
tive fashion. Contralateral limb ABI data were available in
only 43% of cases and, therefore, were not reflective of the
entire study population. Furthermore, the poor correlation
between the ABI and severity of ischemia in patients with
diabetes with calcified vessels is well recognized. In the final
analysis, clinical judgment, aided with noninvasive arterial
and venous testing, remains paramount in designing the
optimal reconstructive strategy for this challenging group
of patients. A flexible approach, including CGSV as a
preferred option in most patients in whom it is available,
has resulted in long-term bilateral limb preservation for
most patients with inadequate ipsilateral vein.
CONCLUSION
Many factors come into consideration in the choice of
alternative conduits for the patient with critical limb isch-
emia without a usable IGSV. Our general approach has
been to use the best conduit available for the clinical
problem at hand, avoiding the CGSV in patients with
clinical evidence of significant ischemia in the contralateral
limb and preserving the arm veins in patients with antici-
pated dialysis access needs. This study confirms the superi-
ority of the CGSV over SSAV and ACV grafts for autoge-
nous infrainguinal arterial reconstruction. In addition to
improved patency, technical expediency, and less frequent
reinterventions favoring CGSV use, our experience sug-
gests that the long-term outcome of the contralateral limb
is not compromised with this approach, even among pa-
tients with diabetes. Because there appears to be no intrin-
sic advantage to “saving the vein” for the contralateral leg,
we believe that the CGSV is the preferred alternative con-
duit for most patients without adequate IGSV for infrain-
guinal arterial reconstruction.
We thank Ms Julie Lombara for maintenance of the
vascular registry, retrieval of data, and assistance in statisti-
cal analyses.
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DISCUSSION
Dr Frank LoGerfo (Boston, Mass). I do not have an easy
explanation for the difference between your results and the results
from Dartmouth as reported by Wallace Terry in terms of the fate
of the contralateral limb when you do a bypass in a patient with
diabetes where there is tissue loss. We have consistently found a
high need for bypass in that contralateral limb, as you know, on the
order of 60% within 3 years. I think that is similar to what was
found at Dartmouth, and others have reported similar sorts of data.
I would have to say that it is unusual to see a patient with diabetes
requiring arterial reconstruction for tissue loss where the other leg
is perfectly normal at the time of that intervention. So, there may
be some difference there. I suppose if we saw patients who had
perfectly normal circulation in the opposite leg that might explain
it, but otherwise I do not have a good explanation. One thing you
do lose when you use the contralateral vein is the option for an in
situ bypass, and again, in patients with diabetes, we so often have to
go to distal vessels for the reconstruction that we prefer that
conduit. I cannot honestly say that it is better. It is certainly easier.
Dr David Chew. Thank you, Dr LoGerfo. With regards to
the last point, we and other authors have shown that greater
saphenous vein, when used in an in situ or a nonreversed trans-
posed conıguration, works equally well. Currently, we do very few
in situ bypasses. Our preference is to take the vein out, lyse the
valves, and then perform the bypass in order to have greater
flexibility with using the vein.
We had 50% diabetics and about 93% with critical ischemia.
Fifty percent of these patients had tissue loss. Our reintervention
rate for the contralateral limb was no different from the Dartmouth
study where only 30% of contralateral limbs required intervention
at 5 years by life table analysis and the overall contralateral limb
intervention rate was only about 20%. Our preference is to go with
the simpler procedure because the quality of the contralateral
greater saphenous vein is more predictable than arm vein and we
are more often able to achieve this bypass with just a single segment
of vein, rather than having to put bits and pieces of veins together.
Dr Anil Hingorani (Brooklyn, NY). Practically speaking,
let’s say you need to do a femoral-dorsalis on the right leg, the vein
has been taken for a CABG, and the patient does not have pulses,
as Dr LoGerfo said, and has an superficial femoral artery occlusion
on the other leg. What do you do?
Dr Chew. Does the contralateral leg require a bypass?
Dr Hingorani. The other leg is asymptomatic. Let’s just
assume that from the outset that patient has tissue loss in the right
leg only and has an asymptomatic left superficial femoral artery
occlusion.
Dr Chew. And no severe venous stasis disease that would
deter us from taking vein from the leg? Well, we would take the
vein from the contralateral leg.
Dr Hingorani. Even though there are no pulses and you may
end up with a wound complication in the lower leg?
Dr Chew. We would first do an ABI and noninvasive hemo-
dynamic study to make sure that the circulation in the contralateral
limb was not too diseased. In general, I think if the ABI in the other
leg is above 0.5, we would be quite comfortable taking vein from
that leg. We always start the vein harvest in the groin and try to
limit the length of vein removed. We try not to extend the harvest
incision below the upper calf in a patient with compromised
circulation.
Dr Hingorani. Did you use ABIs in your study?
Dr Chew. The ABI data were only available in 40% of our
patients, which is why I did not present the data. In the 40% of
patients, which was close to 100 patients, the contralateral ABI
ranged from about 0.32 to greater than 1. The mean and median
was about 0.8, but I am not sure how representative this was
because it only reflected 40% of the total patient population.
Dr Frank Pomposelli (Boston, Mass). I wanted to compli-
ment you on a good paper and for bringing to light a longstanding
difference of opinion with our neighbors across the street about
how to deal with this problem.
I would just point out a few important differences between
your study and ours. In our paper, about 90% of our patients had
diabetes. Although I do not know for sure, I think there was a
higher number of redo procedures in your patient population than
in ours and more of our patients who were having primary proce-
dures. Of course, we use angioscopy routinely in trying to evaluate
the quality of arm vein, and I think if you do that, it is a much more
accurate way of determining whether you have a good quality arm
vein conduit or not. That is why if you actually look at your results
with contralateral saphenous vein they are really not that much
better than the results we have recently reported with over 500 arm
vein grafts (Faries et al. J Vasc Surg 2000;31:50). Probably the
reason for that is not because contralateral saphenous vein is not a
better conduit (I think it probably is) but because I think you had
a higher incidence of redo reconstructions where you will most
likely have a worse outcome.
I would also add that it has been my clinical experience with
patients, particularly diabetic patients, that they are not very ex-
cited about the prospect of you harvesting a vein from their other
leg. Even though they may not lose their leg as a result of it, they
can have serious wound morbidity. Leg swelling, pain, and discom-
fort on their sound limb is something that many patients find quite
anxiety-provoking, with good reason.
I enjoyed your paper.
Dr Chew. Thank you. We did indeed learn quite a bit on arm
vein harvesting and the natural history of these grafts from the
Deaconess group. I think from that same paper originally describ-
ing arm vein as the preferred conduit in patients lacking ipsilateral
greater saphenous vein, when you used angioscopy, you could only
find good vein 50% of the time, and in the other half, you had to do
some kind of upgrade and clean up of the vein. I guess the message
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 6 Chew et al 1091
we want to say today is to be flexible and to keep the operation
simple. Not everyone is familiar with angioscopy and not every
institution has it. Therefore, I think a flexible approach, including
the use of the contralateral greater saphenous vein in properly
selected patients, works just as well, with little detrimental effect on
the contralateral limb.
Dr Dan Walsh (Lebanon, NH). I would just like to make
some comments and ask a question; that is, I am not so sure that
this is that terribly different from the Dartmouth experience in the
sense that the intervention rate was identical. The one thing that
interests me is that if I understood your slide correctly you are
saying that the people that you operated on who did not have
diabetes had exactly the same progression rate of disease as did
diabetics. To my mind, that flies in the face of vascular knowledge
in the sense that, to me, diabetics who have disease in one leg tend
to have progressive disease in the other leg. They have a very high
incidence of contralateral—if you amputate a diabetic’s leg, they
have a very high rate of a contralateral amputation. So, it seems to
me that if you went on the assumption (if you looked at the
Dartmouth data and said the other leg is okay, ie, good ABI), we
would not have a problem if they did not have previous big-time
cardiac disease using the contralateral leg. That was not the point
of our study. The point of our study was if you had obvious
generalized vascular disease that a blithe use of the contralateral
vein was likely to find yourself 2 years later standing there saying we
are going to have to use the arm vein now. I am not so sure that the
findings in this are terribly different except with one exception and
that is we really found diabetes as a predictor of significant bilateral
disease and the need for future intervention. It would bother me if
you said no, that is not true, because it seems to me it is pretty well
known that that is true.
Dr Chew. About 50% of our patients had diabetes in this
study, and when we looked at the outcome in the two groups, we
just could not show that there was a difference. It was an interest-
ing finding to us, but there was no difference in requirement for
contralateral limb bypass or amputation. If a diabetic patient
develops disease somewhere down the line after the contralateral
leg vein has been used, then we would move on to whatever
alternative conduit is available at that point in time. We try to treat
the immediate problem there and then, get the patient over the
current illness, and deal with the subsequent problems at a later
time.
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